Skip to main content
Equibles
NSTM logo

NSTM · NovelStem International Corp.

Track NSTM — free

Use NSTM with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NSTM.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.01 At close · Oct 7
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.”
View the 10-Q filed Aug 14, 2026
Market Cap
$493,324
Shares
49.33M
Volume · Oct 7 11.94K Avg daily vol (13 sessions) 70.25K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.01 Open$0.01 Day$0.01–0.01 52W close$0.01–0.03 Avg vol 30d49K Short int176 · 0.0% float · 1.0d Short vol40% DataJan 2020–Oct 2026 Filing10-Q · Aug 14

Up next

Latest filing: 10-Q
filed Aug 14, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$510,701
Trailing 12 months
Net income (TTM)
−$307,559
Trailing 12 months
Revenue growth YoY
+45.8%
Year over year
Operating margin
-925.2%
Trailing 12 months
P / E (TTM)
0.2
Trailing earnings · reciprocal yield 526.3%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$1.24M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+3.3%
Year over year · more shares
Price change (1Y)
-52.5%
Trailing year
Short interest
—
Latest settlement
View all 122 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 17.3 · elevated Equity put/call 0.56
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −88%
below
Price vs 50-day avg −27%
below
RSI (14) 46
neutral
MACD trend Negative
52-week position 0%
near low
Momentum
relative strength
Very Weak
1-month return −5%
trailing
6-month return −84%
trailing
YTD return −5%
this year
Relative strength −95%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
0.00% of float · ▬ 0.0% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Fundamentals
Weak
Revenue growth −42%
Y/Y
EPS growth +171%
Y/Y
Free cash flow $-251.6K
Quant / Vol
risk profile
Very High
Volatility 411%
annualized · 1-yr
Max drawdown −97%
past year
ATR 21.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 2 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−88% Bearish
Price vs 50-day avg
−27% Bearish
RSI (14)
46 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Market signals — smart money & positioning
No clear signal
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
0.00% of float · ▬ 0.0% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Price context
position in its 52-week range
Range low $0 Now $0 · 0% Range high $0
vs 200-day avg -88% vs 50-day avg -27%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Diagnostics & Research — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
NSTM
NovelStem International Corp.
this stock
$493,324 -5.0% -42.3% — 0.0%
TMO
Thermo Fisher Scientific Inc.
 $251.20B +18.6% +14.5% 36.6 1.5%
DHR
Danaher Corp /De/
 $157.64B -2.0% +8.5% 39.8 1.3%
NTRA
Natera, Inc.
 $58.51B +77.2% -2.8% — 4.4%
A
Agilent Technologies, Inc.
 $48.56B +27.1% +6.4% 33.9 1.9%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Short & Settlement
Short Interest
Shares short
176
Days to cover
1.0d
Change
0 sh
View
Short Volume
Short vol %
40%
As of
Sep 28, 2026
Short Total
View
Fails to Deliver
FTD shares
1.6K
Value
$33
As of
Dec 26, 2025
View
Off-Exchange
Off-exchange %
100.0%
Week of
Sep 14, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$2.4M
EPS diluted
$0.05
View
Filings
SEC Filings
Latest
10-Q
Filed
Aug 14, 2026
This year
3
View

Performance

5D 20D 120D MTD YTD
NSTM +0.0% -5.0% -84.2% +0.0% -5.0%
SPY +1.9% +1.9% +10.8% +1.9% +14.0%
vs SPY -1.9% -6.9% -94.9% -1.9% -19.0%
Key facts CIK 912544 Visit website Investor relations